Effect of Intramuscular Adipose Tissue Content on Prognosis in Patients Undergoing Hepatocellular Carcinoma Resection

Journal of Gastrointestinal Surgery

Volumn 19, Issue 7, 2015, Pages 1315-1323

  Kaibori, Masaki ^a   Ishizaki, Morihiko ^a   Iida, Hiroya ^a   Matsui, Kosuke ^a   Sakaguchi, Tatsuma ^a   Inoue, Kentaro ^a   Mizuta, Toshihiko ^b   Ide, Yasushi ^b   Iwasaka, Junji ^c   Kimura, Yutaka ^a   Hayashi, Fumikazu ^d   Habu, Daiki ^d   Kon, Masanori ^a  

^a KANSAI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^b SAGA UNIVERSITY   (Japan)

^c KANSAI MEDICAL UNIVERSITY   (Japan)

^d Osaka Prefecture University   (Japan)

Author keywords

Hepatectomy; Intramuscular adipose tissue content; Liver cancer; Predictors; Skeletal muscle fat accumulation

Indexed keywords

ADIPOSE TISSUE; ADVERSE EFFECTS; AGED; BLOOD TRANSFUSION; CARCINOMA, HEPATOCELLULAR; COMPLICATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LIVER; LIVER NEOPLASMS; LIVER RESECTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPERATIVE BLOOD LOSS; PATHOLOGY; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; SKELETAL MUSCLE; SURVIVAL RATE;

ADIPOSE TISSUE; AGED; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; CARCINOMA, HEPATOCELLULAR; DIABETES MELLITUS, TYPE 2; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MUSCLE, SKELETAL; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84931574058     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-015-2838-8     Document Type: Article

References (47)

1. Bosch X, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19: 271–285.
2. Taylor-Robinson SD, Foster GR, Arora S, et al. Increase in primary liver cancer in the UK 1979–94. Lancet 1997; 350: 1142–1143.
3. EI-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745–750
4. BruiX J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet 2009; 373: 614–616.
5. BruiX J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020–1022.
6. Sabel MS, Lee J, Cai S, et al. Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol 2011; 18: 3579–3585.
7. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenia obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008; 9: 629–635.
8. Montano-Loza AJ, Meza-Junco, Prado CM, et al.: Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol 2012; 10: 166–173.
9. Tan BH, Birdsell LA, Martin L, et al.: Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 2009; 15: 6973–6979.
10. van Vledder MG, Levolger S, Ayez N, et al.: Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg 2012; 99: 550–557.
11. Harimoto N, Shirabe Y, Yamashita YI, et al.: Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg 2013; 100: 1523–1530.
12. Miljkovic I, Zmuda JM.: Epidemiology of myosteatosis. Curr Opin Clin Nutr Metab Care 2010; 13: 260–264.
13. Marchesini G, Forlani G, Bugianesi E. Is liver disease a threat to patients with metabolic disorders? Ann Med 2005; 37: 333–346.
14. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance fot hepatic and extrahepatic disease. Gastroenterology 2004; 126: 586–597.
15. Valgimigli M, Valgimigli L, Trere D, et al. Oxidative stress EPR measurement in human liver by radical-probe technique. Correlation with etiology, histology and cell proliferation. Free Radic Res 2002; 36: 939–948.
16. Muller MJ, Pirlich M, Balks HJ, Selberg O. Glucose intolerance in liver cirrhosis: role of hepatic and non-hepatic influences. Eur J Clin Chem Clin Biochem 1994; 32: 749–758.
17. Kitajima Y, Eguchi Y, Ishibashi E, et al.: Age-related fat deposition in multifidus muscle could be a marker for nonalcoholic fatty liver disease. J Gastroenterol 2010; 45: 218–224.
18. Kitajima Y, Hyogo H, Sumida Y, et al.: Severity of non-alcoholic steatohepatitis is associated with substitution of adipose tissue in skeletal muscle. J Gastroenterol Hepatol 2013; 28: 1507–1514.
19. Strasberg SM, Belghiti J, Clavn P-A, et al.: The Brisbane 2000 terminology of liver anatomy and resection. Terminology Committee of the International Hepato-Pancreato-Biliary Association. HPB 2000; 2: 333–339.
20. Couinaud C (ed): “Le Foie: Etudes Anatomiques et Chirurgicales.” Paris: Masson, 1957.
21. Sobin LH, Wittekind C (eds): “TNM Classification of Malignant Tumours.” 5th ed. New York: Wiley, 1997.
22. Englesbe MJ, Patel SP, He K, et al.: Sarcopenia and mortality after liver transplantation. J Am Coll Surg 2010; 211: 271–278.
23. Goodpaster BH, Thaete FL, Simoneau JA, et al.: Subcutaneous abdominal fat and thigh muscle muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 1997; 46: 1579–1585.
24. Pan DA, Lillioja S, Kriketos AD, et al.: Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 1997; 46: 983–988.
25. Phillips DI, Caddy S, Ilic V, et al.: Intramuscular triglyceride and muscle insulin sensitivity: Evidence for a relationship in nondiabetic subjects. Metabolism 1996; 45: 947–950.
26. Kelley DE, Slasky BS, Janosky J: Skeletal muscle density: Effects of obesity and non-insulin-dependent diabetes mellitus. Am J Clin Nutr 1991; 54: 509–515.
27. Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med 2006; 119: S10-16.
28. Timmers S, Schrauwen P, de Vogal J: Muscular diacylglycerol metabolism and insulin resistance. Physiol Behav. 2008; 94: 242–251.
29. Lowell BB, Shulman GI: Mitochondrial dysfunction and type 2 diabetes. Science 2005; 307: 384–387.
30. Komura T, Mizukoshi E, Kita Y, et al.: Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. Am J Gastroenterol 2007; 102: 1939–1946.
31. Kawamura Y, Ikeda K, Arase Y, et al.: Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis. J Gastroenterol Hepatol 2008; 23: 1739–1746.
32. Huo TI, Lui WY, Huang YH, et al.: Diabetes mellitus is a risk factor for hepatic decompensation in patients with hepatocellular carcinoma undergoing resection: a longitudinal study. Am J Gastroenterol 2003; 98: 2293–2298.
33. Giovannucci E.: Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res 2003; 35: 694–704.
34. Tran TT, Medline A, Bruce WR.: Insulin promotion of colon tumors in rats. Cancer Epidemiol Biomarkers Prev 1996; 5: 1013–1015.
35. Swerdlow AJ, Laing SP, Qiao Z, et al.: Cancer incidence and mortality in patients with insulin-treated diabetes: A UK cohort study. Br J Cancer 2005; 92: 2070–2075.
36. Schiel R, Muller UA, Braun A et al.: Risk of malignancies in patients with insulin-treated diabetes mellitus –results of a population- based trial with 10-year follow-up (JEVIN). Eur J Med Res 2005; 10: 339–344.
37. Chuang TY, Lewis DA, Spandau DF.: Decreased incidence of nonmelanoma skin cancer in patients with type 2 diabetes mellitus using insulin: A pilot study. Br J Dermatol 2005; 153:552–557.
38. Yang YX, Hennessy S, Lewis JD.: Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004; 127: 1044–1050.
39. Facciorusso A.: The influence of diabetes in the pathogenesis and the clinical course of hepatocellular carcinoma: recent findings and new perspectives. Curr Diabetes Rev 2013; 9: 382–386.
40. Kawaguchi T, Taniguchi E, Itou M, et al.: Insulin resistance and chronic liver disease. World J Hepatol 2011; 3: 99–107.
41. Avramoglu RK, Basciano H, Adeli K.: Lipid and lipoprotein dysregulation in insulin resitant states. Clin Chim Acta. 2006; 368: 1–19.
42. Furukawa S, Fujita T, Shimabukuro M, et al.: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004; 114: 1752–1761.
43. Hickman IJ, Jonsson JR, Prins JB, et al.: Modest weight loss and physical activity in overweight patients with chronoc liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut. 2004; 53: 413–419.
44. Katz SC, Shia J, Liau KH,et al.: Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg 2009; 249: 617–623.
45. Tung-Ping Poon R, Fan ST, Wong J.: Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000; 232: 10–24.
46. Kaibori M, Ishizaki M, Matsui K, et al. Perioperative exercise for chronic liver injury patients with hepatocellular carcinoma undergoing hepatectomy. Am J Surg. 2013;206: 202–209.
47. Kaibori M, Ishizaki M, Matsui K, et al. Assessment of preoperative exercise capacity in hepatocellular carcinoma patients with chronic liver injury undergoing hepatectomy. BMC Gastroenterol. 2013; 22;13:119. doi: 10.1186/1471-230X-13-119.